<DOC>
	<DOC>NCT01358266</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.</brief_summary>
	<brief_title>Study Assessing Double-masked Uveitis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Confirmed diagnosis of active uveitis 18 years of age or older Sign informed consent Meet best corrected ETDRS visual acuity Uveitis of infectious etiology Suspected/confirmed central nervous system or ocular lymphoma Primary diagnosis of anterior uveitis Uncontrolled glaucoma Use of topical oculary medication Implanted device Significant ocular disease Lens/media opacities or obscured ocular media Intraocular surgery or treatments Capsulotomy Ocular or periocular infection Pupillary dilation History of herpetic infection Toxoplasmosis or toxoplasmosis scar Ocular malignancy Allergy or hypersensitivity to study drug Participation in other uveitis trial within 30 days Monoclonal antibody treatment or biologic therapy Any systemic condition/infection Immunosuppressive therapy or immunocompromised Malignancy remission Females who are pregnant or lactating and females not using adequate contraceptives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>